Wednesday, January 24, 2018
News
NEWS HOME
»
PRESS RELEASES

AHF: 'Shameless' Gilead Hikes Key AIDS Drug Pricing 6.9% Despite Recent Patent Expiration
  SocialTwist Tell-a-Friend  
   


Date: 11-01-2018 12:48PM
Source: AIDS Healthcare Foundation
Category: General, Consumer Interest, Science & Research, Healthcare & Biotechnology, Pharmaceutical
Location: Los Angeles, United States

Business Wire India

AIDS Healthcare Foundation (AHF), the largest global AIDS organization and a vocal critic of runaway drug pricing and drug profiteering, today blasted Gilead Sciences, Inc. over newly instituted price hikes of 6.9% on three key HIV/AIDS treatments despite the fact that the patent for a key component of each treatment—tenofovir—expired in mid-December.

AHF branded Gilead’s latest pricing action a shameless move by what one expert called “perhaps the most ethically challenged drug company,” in the drug pricing documentary, “Your Money or Your Life.”

In October 2017, as patent expiration loomed for Gilead, AHF called on Gilead to reduce the price of its tenofovir-based drug regimens—including Truvada—by as much as 90%.

The California drug company has made billions off of sales of its tenofovir-based drugs since the FDA first approved Gilead’s tenofovir disoproxil fumarate (TDF), branded as Viread, on October 26, 2001. That patent expired on December 15, 2017, with the patent on a pediatric version of the drug set to expire in early 2018. All the while Gilead simultaneously sought to ‘evergreen’ and manipulate the patent extension process.

“It is nothing short of grotesque that Gilead raised the price of Truvada by 6.9% despite the fact that it is now off patent and generic,” said Michael Weinstein, President of AIDS Healthcare Foundation. “This is a lifesaving HIV/AIDS treatment that they have already made billions off of and they are now trying to squeeze the well dry. Also, if Gilead is truly committed to providing and enhancing access to Truvada for use as pre-exposure prophylaxis or PrEP to prevent HIV acquisition by uninfected individuals, it is unconscionable for them to also charge this steep price on a now generic medicine. We call on other AIDS and community groups nationwide to join us in calling on Gilead to reduce its pricing, and also loudly renew our October call on Gilead to reduce the price of its tenofovir-based drug regimens—including Truvada—by 90% as well as on other combination therapies using tenofovir that Gilead makes in partnership with companies like BMS and Janssen.”

Since FDA approval of the drug in 2001, the TDF formulation of tenofovir has become a cornerstone of other big money Gilead combination HIV/AIDS treatment therapies beyond Viread, including:

  • Atripla (efavirenz + tenofovir disoproxil fumarate + emtricitabine—made in partnership with Bristol-Myers Squibb);
  • Complera (rilpivirine + tenofovir disoproxil fumarate + emtricitabine—made in partnership with Janssen Theraputics);
  • Stribild, the four-drug-in-one tablet (elvitegravir + cobicistat + tenofovir disoproxil fumarate + emtricitabine);
  • Truvada (tenofovir disoproxil fumarate + emtricitabine), Gilead’s blockbuster HIV/AIDS treatment that is also the medication component used for pre-exposure prophylaxis (PrEP) to prevent HIV acquisition; and
  • Viread (tenofovir disoproxil fumarate or ‘TDF’ - previously cited above.

In February 2016, AHF filed a lawsuit against Gilead over its manipulation of the patent system in order to derail competition to its HIV medicines. As reported at the time by Ed Silverman on the health news service, STAT, “At issue is tenofovir, or TDF, which is a cornerstone of the combination HIV treatments that Gilead sells. The patent on the TDF compound expires in December 2017 and Gilead hopes to replace it with a modified version known as TAF. The patent on TAF doesn’t expire until May 2022, and the prospect of nearly five more years of sales without generic competition is extremely valuable.”

He also noted, “There is another important difference between the two compounds — TAF is more potent and causes fewer side effects, notably bone damage and kidney toxicity.”

In 2014, in anticipation of Viread’s upcoming patent expiration, Gilead pulled a much more efficacious 30mg lower dose version of Viread off its development shelf and instead began the evergreening process by filing its first New Drug Application (NDA) for the modified Viread molecule, tenofovir alafenamide, or TAF (later branded Vemlidy).

It should be noted that Teva, an Israeli multinational pharmaceutical company and generic drug manufacturer, is allowed to begin production of a generic version of Viread as of December 15, 2017, resulting from its litigation against Gilead. Truvada, which contains the older version of Viread combined with a second Gilead drug called Emtriva, can also go generic as of December 2017.

What is most telling about Gilead’s corporate conscience—or lack thereof—is that after many years of incredible successes, this newer TAF version of Viread, which has a significantly better adverse event profile (particularly regarding renal side effects that impact African Americans much more) was reportedly left on the shelf post-development by Gilead Sciences for years. The reason for doing so is obvious: to maximize profits via the evergreening process by waiting until just the right time to begin filing new drug applications for all previously approved combination therapies. This effectively extends patent life of Gilead’s drug portfolio and greatly enhances the profit margins for Gilead.

AIDS Healthcare Foundation (AHF), the largest global AIDS organization, currently provides medical care and/or services to more than 855,000 individuals in 39 countries worldwide in the US, Africa, Latin America/Caribbean, the Asia/Pacific Region and Eastern Europe. To learn more about AHF, please visit our website: www.aidshealth.org, find us on Facebook: www.facebook.com/aidshealth and follow us on Twitter: @aidshealthcare.



CONTACTS :

AIDS Healthcare Foundation
Ged Kenslea
Senior Director, Communications
Telephone: (323) 308-1833
Mobile: (323) 791-5526
gedk@aidshealth.org

More Press Releases

International Research Organization Honors Health Care Fraternity for their Outstanding Work

TRAVELSPICE Wins Travel-tech Startup of the Year 2018 Award and Grant of Rs 15 lakhs from Government of Karnataka

Win 2 lakhs this Patriotic Day at Adda52 Rummy in Republic Day Tournament

IDEMIA Announces Acquisition of Otono Networks and Its eSIM Orchestration Solution

Global Eagle to Elevate Airline Passenger Experience Over North America with More SES HTS Satellite Capacity

Augmont adds 500,000 Offline Touch Points to its Net, Spreads Wings to Smaller Towns

Neil Diamond Announces Retirement from Concert Touring; Australian and New Zealand Tour Dates Cancelled

AECOM defines infrastructure’s next chapter with launch of its inaugural global report: The Future of Infrastructure

Takeda Recognized as a Global 100 Most Sustainable Corporation for Third Consecutive Year

Tata Housing Launches 'Vertillas' Ultra-luxury Residences at Primanti in Gurugram

PMI’s Salary Survey Reveals that Project Management Practitioners with the PMP Certification Earn 23% More

Bacardi to Acquire Patrón Tequila

BMW India Announces an Exclusive Partnership with Bengaluru International Airport

Häfele Unites Design Possibilities with Form and Functionality at its New State-of-the-art Showroom in Bangladesh

IC3 Announces the Third Edition of the 2018 Annual IC3 Conference to Provide an Impetus to Career Counseling in High Schools

Large Deals across Multiple Verticals Drive a 26 percent YoY USD Revenue Growth for L&T Technology Services

Commvault Powers New HPE GreenLake Backup Solution to Bring Enterprise-class Data Protection and Reliability to Customers

European Commission Approves ADCETRIS® (brentuximab vedotin) for CD30-Positive Cutaneous T-Cell Lymphoma after One Prior Systemic Therapy– Providing an Innovative Treatment Option to Patients

Hilton Led Hospitality Industry in Customer Innovations and Recorded Best Ever Growth in 2017

HackerEarth Recruit Continues Exceptional Customer Momentum; Used by More than 4000 Enterprises

MAIT Strongly Advocates "Make in India for the World" through its Electronics Manufacturing Summit

Calvin Klein, Inc. Announces the Spring/Summer 2018 Calvin Klein Underwear and Calvin Klein Jeans Global Advertising Campaign

Ferring enters into worldwide OmniAb® platform license agreement with Ligand

Hybrid and Electric Vehicle Growth in India Driven by Government Incentives and Changing Customer Attitudes

Panasonic LUMIX GH5 Supports Yasunaga Ogita, a Polar Explorer, in Japan's First Solo South Pole Expedition Without Resupplies

Applied DNA Expands Internationally with New Central DNA Testing Laboratory in India

New Study Investigates the Clinical Utility of ORi™, Masimo Oxygen Reserve Index™, in Obese Patients

Octapharma:Low inhibitor rate with octanate® in previously untreated patients (PUPs) with severe haemophilia A

Treamis World School Marks its Decennial Celebrations in Style!

Green Initiatives in India to be Recognized at the One Globe Awards

Dailyhunt Launches Newzly, a News-in-Brief App, in Nine Languages

Jaipuria Group Plans to Invest 500 crores for Expansion across 5 States

 
TRENDING TOPICS
 
 
 
CITY NEWS
MORE CITIES
INDIA WORLD ASIA
'Odisha Bandh' to protest suicide of K...
World Cup arrives in Sri Lanka to kick o...
How cruise vacations are good for your w...
Udacity announces 'Flying Cars Nanodegre...
Dilip Buildcon declared L-1 bidder for N...
JMC Projects Secures new orders worth Rs...
More...    
 
 Top Stories
Haqqani network commander, two othe... 
Marketing tech firm Netcore expands... 
Lalu Prasad, Jagannath Mishra get 5... 
India reach 45/2 at lunch on Day 1... 
Military bands to hit the right not... 
Equities scale new highs amid flat ... 
Bankers suggest lowering corporate ... 
At Disneyland Paris, age is just a ...